NASDAQ · DMAAR
Drugs Made In America Acquisition Corp. Rights
Financial Services · Shell Companies
$0.17
Up+$0.02 (+10.00%)
Updated Aug 14, 2026, 1:37 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.98M
- P/E ratio
- 41.6
- Dividend yield
- 0.00%
- 52-week range
- $0.04 – $0.21
- Volume
- 33.78K
- Avg. volume
- 87.91K
Price performance
DMAAR price history
1M range · 21 trading sessions · Daily adjusted prices
DMAAR closed at $0.17 after 21 trading sessions, up 43.60% for the selected period.
- Last close
- $0.17
- Period change
- +43.60%
- Period low
- $0.11
- Period high
- $0.17
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.14 | $0.165 | $0.14 | $0.165 | 33.78K |
| Aug 12, 2026 | $0.158 | $0.158 | $0.1494 | $0.15 | 4.83K |
| Aug 11, 2026 | $0.14 | $0.1545 | $0.14 | $0.15 | 15.09K |
| Aug 10, 2026 | $0.145 | $0.165 | $0.1449 | $0.1601 | 37.52K |
| Aug 7, 2026 | $0.1501 | $0.1501 | $0.1499 | $0.15 | 15.52K |
| Aug 6, 2026 | $0.16 | $0.16 | $0.16 | $0.16 | 435.29 |
| Aug 5, 2026 | $0.1672 | $0.1672 | $0.16 | $0.16 | 960 |
| Aug 4, 2026 | $0.1301 | $0.16 | $0.1301 | $0.155 | 3.23K |
| Aug 3, 2026 | $0.1501 | $0.1696 | $0.1501 | $0.1696 | 1.06K |
| Jul 31, 2026 | $0.1696 | $0.1696 | $0.15 | $0.16 | 8.04K |
| Jul 30, 2026 | $0.1696 | $0.1696 | $0.1511 | $0.1595 | 3.12K |
| Jul 29, 2026 | $0.17 | $0.17 | $0.16 | $0.16 | 3.69K |
| Jul 28, 2026 | $0.15 | $0.16 | $0.15 | $0.1599 | 2.28K |
| Jul 27, 2026 | $0.16 | $0.17 | $0.15 | $0.16 | 75.39K |
| Jul 24, 2026 | $0.162 | $0.17 | $0.1583 | $0.164 | 238.44K |
| Jul 23, 2026 | $0.1625 | $0.17 | $0.1625 | $0.1699 | 30.07K |
| Jul 22, 2026 | $0.1815 | $0.21 | $0.1622 | $0.1622 | 166.61K |
| Jul 21, 2026 | $0.1726 | $0.1805 | $0.1641 | $0.1699 | 671.09K |
| Jul 20, 2026 | $0.0905 | $0.11 | $0.0903 | $0.11 | 262.57K |
| Jul 17, 2026 | $0.0999 | $0.1148 | $0.0903 | $0.1147 | 34.39K |
| Jul 16, 2026 | $0.1149 | $0.1149 | $0.1149 | $0.1149 | 110 |
Latest DMAAR news
The latest Smart Investors Daily articles mentioning DMAAR.
Stock researchCompany · Overview
DMAAR research
Overview
Company profile and research snapshot.
Company profile
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
